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Abstract 
Authors analysed a number of 4588 (52, 
24% over 50 years old) patients operated for 
cerebral tumors in the Clinic Emergency 
Hospital “Bagdasar-Arseni” from 
Bucharest, between 2000-2010, with 
peculiar attention to the concordance 
between the preoperative and postoperative 
diagnosis, related to the actual policy to 
evaluate a neurosurgical patient before 
surgery. 903 cases were cerebral metastases 
and 69,5% aged over 50 years old. In 9,7% 
of cases we recorded a preoperative 
misdiagnosis of a metastasis due to few 
main reasons: unavailable information 
about a present primitive cancer, 
treacherous MRI image with a single 
confusing appearance of a cerebral lesion, 
age less than 50 years old, clinical 
presentation and biological evaluation 
inconsistent with malignancy. Authors 
point that these situations can have serious 
consequences related to professional 
competence, deterioration of the patient-
doctor relationship, increasing costs for 
completion of diagnosis and treatment, and 
inadequate information about patient’s 
prognosis. 
Keywords: cerebral metastases, 
deontological issues, diagnosis, concordance 
 
Introduction 
Cerebral metastases represent the spread 
of a neoplasm from a primary site to the 
brain. The most common primary tumors 
metastatic to brain include lung cancer 
(adenosquamous and small cell especially), 
breast cancer, melanoma, renal cancer and 
colon cancer. Metastases are frequently 
found at the grey/white junction. They are 
usually well demarcated from the brain 
parenchyma. The majority of metastases 
(greater than 75%) are found 
supratentorially with the minority (less than 
10%) found in the brainstem. The patients 
present with signs and symptoms referable 
to either increased intracranial pressure or 
focal pathology (4). A contrast enhanced 
MRI will give the best view of suspected 
metastatic cancers. Therapy for the 
metastatic cancer is based upon the therapy 
that would be or has been given to the 
primary cancer. In any event corticosteroids 
can be useful for reduction of patients' 
symptoms. Metastases to the brain is the 
most feared complication of systemic 
cancer and the most common intracranial 
tumor in adults. The incidence of brain 
metastasis is rising with the increase in 
survival of cancer patients. Currently, 
cancer patients live longer as a result of 
important advances in cancer diagnosis and 
management, and in particular, the 
 
 
 
Romanian Neurosurgery (2011) XVIII 3: 240 - 254          241 
 
 
 
widespread use of MRI to detect small 
metastases. Approximately 40% of 
intracranial neoplasms are metastatic (9). 
Multiple, large autopsy series suggest that, 
in order of decreasing frequency, lung, 
breast, melanoma, renal, and colon cancers 
are the most common primary tumors to 
metastasize to the brain. Brain metastases 
are an increasingly important cause of 
morbidity and mortality in cancer patients. 
Thus, brain metastases presents a 
therapeutic challenge for the treating 
physician and is an emotionally and 
physically debilitating event for the patient. 
Early diagnosis and aggressive treatment of 
brain metastasis may result in remission of 
brain symptoms and may enhance the 
quality of the patient's life and prolong 
survival (2, 12). The radiologist plays a 
primary role in the management of cancer 
patients by helping detect, localize, and 
diagnose the lesion. The prognosis for 
patients with brain metastases typically is 
poor (13). Of particular relevance to 
imaging is the fact that for patients with a 
solitary brain metastasis who undergo 
treatment by surgical resection, the survival 
rate after 1 year is approximately doubled. 
Most available treatment is palliative; 
however, consideration should be given to 
prolonging the patient's quality of life 
through specific therapy to the brain (15). 
Most patients with a known primary tumor 
undergo imaging studies when neurologic 
signs and symptoms develop. Magnetic 
resonance imaging (MRI) with contrast 
enhancement currently is the procedure of 
choice, because MRI is more sensitive and 
specific than other imaging modalities in 
determining the presence, location, and 
number of metastases. Contrast-enhanced 
computed tomography (CT) scanning is 
used widely because of its accessibility and 
low cost. With regard to screening for 
intracranial metastases, no consensus has 
been reached concerning when to use CT 
or MRI for initial staging evaluation of a 
patient with cancer. However, brain MRI 
for patients with primary cancers that 
frequently metastasize to the brain (eg, 
bronchogenic carcinoma) is probably cost 
effective. Numerous studies have shown 
that contrast-enhanced MRI detects 2-3 
times as many lesions as contrast-enhanced 
CT, especially lesions less than 5 mm in 
diameter. In addition, approximately 20% of 
patients with solitary metastatic lesions on 
CT show multiple lesions on MRI. The 
decision to perform imaging for patients 
with other cancers is made on the basis of 
the clinical evaluation. In the presence of 
multiple cerebral metastases from an 
unknown primary source, a limited search 
for the primary tumor is of value; such a 
search includes a chest radiograph, breast 
examination and mammography, and 
abdominal ultrasound (US). An extensive 
search for an occult malignancy is 
unrewarding. Surgery may be required for 
patients presenting with a solitary 
intracranial tumor or to search for a 
possible primary tumor. They occur some 
limitations of techniques: approximately 
one third of patients operated on for a 
single cerebral metastasis diagnosed with 
contrast-enhanced CT probably have more 
than one lesion. Contrast-enhanced MRI is 
more sensitive than CT in detecting the 
number of cerebral metastases. The 
diagnosis of a brain tumor is best made by 
cranial MRI. This should be the first test 
obtained in a patient with signs or 
symptoms suggestive of an intracranial 
mass. MRI is superior to CT and should 
always be obtained with and without 
contrast material such as gadolinium. A 
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contrast-enhanced CT scan may be used if 
MRI is unavailable or the patient cannot 
undergo MRI (eg, because of a pacemaker). 
CT is adequate to exclude brain metastases 
in most patients, but it can miss low-grade 
tumors or small lesions located in the 
posterior fossa. Tumor calcification is often 
better appreciated on CT than on MRI. 
Body positron emission tomography (PET) 
scans performed for staging of systemic 
malignancies have a sensitivity of only 75% 
and a specificity of 83% for identification of 
cerebral metastases. Therefore, they are less 
accurate than MRI, which remains the gold 
standard. On CT or MRI, most brain 
metastases are enhancing lesions 
surrounded by edema, which extends into 
the white matter. Unlike primary brain 
tumors, metastatic lesions rarely involve the 
corpus callosum or cross the midline. The 
radiographic appearance of brain metastases 
is nonspecific and may mimic other 
processes, such as infection. Therefore, the 
CT or MRI scan must always be 
interpreted within the context of the 
clinical picture of the individual patient, 
particularly as cancer patients are vulnerable 
to opportunistic CNS infections or may 
develop second primaries, which can 
include primary brain tumors. Magnetic 
resonance spectroscopy (MRS) and 
perfusion imaging can help differentiate 
low-grade from high-grade brain tumors 
but cannot distinguish different tumor 
types of the same grade. 
Material and methods 
Between 2000-2010, 4588 files of 
patients operated for a brain tumor in the 
Clinic Emergency Hospital “Bagdasar-
Arseni” from Bucharest, were 
retrospectively analyzed with peculiar 
attention to the concordance between the 
preoperative and postoperative diagnosis. 
903 cases (100%) were recorded as cerebral 
metastases of different etiologies, after 
pathological examinations of the specimens. 
We recorded age, sex, symptoms on 
presentation and their duration, type of 
investigations and lesions description, 
clinical and biological profile, and if existed 
a known primary tumor. Actual protocol 
before operation in a patient with a brain 
tumor supposes: cerebral CT scan native 
and contrast, cerebral MRI native and 
contrast, MRI angiography when necessary, 
DSA angiography in specific cases. Patient 
has a standard chest x-ray, skull x-ray, EEG, 
EKG, cardiologic examination after 45 years 
old, ophthalmologic evaluation, standard 
blood test and urine test. Patient’s files 
analyze were done due to electronic patient 
database from our hospital and statistical 
data was obtained by Microsoft Excel ®. 
Concordance analysis was done by assigned 
key-words, inconsistent data was manually 
evaluated for excluding/including the cases 
related to different written expressions.  
Results 
773 cases (85,6%) presented initially a 
single cerebral metastases, and 556 patients 
(61,5%) were investigated by contrast CT 
scan and contrast MRI scan. 347 patients 
were operated only after a contrast CT (115 
patients-12,7%) or MRI (232 patients-
25,69%).  
From the 773 cases (100%) operated 
with a single lesion, in 590 cases the 
primary tumor was not known before 
neurosurgical procedure (76,32%). In the 
time of hospitalization 309 cases (40%) 
benefitted of other investigations (whole-
body contrast CT, bronchoscopy, digestive 
endoscopy, etc) and the primary cancer was 
documented. 281 patients (36,35%) 
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remained cases with a non-documented 
primary cancer were referred to the 
oncology department for other specific 
investigations and supplementary 
pathologic histochemistry analysis for 
identifying the organ of tumor origin.108 
patients (13,19%) obtained a diagnose of the 
primary cancer origin during the oncologic 
treatment. From a number of 173 cases 
(22,38%) with an unknown origin of the 
primary tumor, 123 continued 
investigations and treatments and a 
diagnosis was possible in the lifetime and 50 
patients (6,46%) deceased without the 
primary cancer known.  
In 75 patients (9,70% )operated for a 
single cerebral lesion, without a known 
primary tumor, we recorded a misdiagnose 
of a cerebral metastasis , after analyzing the 
concordance between the preoperative and 
postoperative diagnosis. We analyzed the 
most important criteria for a correct 
diagnosis: 1) history and symptoms- history 
was not conclusive for a primary known 
cancer. The most frequent symptom at 
presentation was headache, dizziness, and 
memory disturbances. 2) age: medium age 
was 51,6 years old, they were 34 females 
and 41males; 3) diagnose imaging study- 35 
patients were investigated by both CT and 
MRI, 22 had only MRI and 18 had only a 
CT; most of the situations revealed a 
confusing image with a primary brain 
tumor or cerebral abscess. 4) clinical and 
biological standard preoperative evaluation 
was inconsistent with malignancy- absence 
of any inflammatory syndrome, no 
suspicion of cancer on the standard 
evaluations. In all cases clinical and 
biological profile was not conclusive for a 
neoplastic disease. 
 
 
 
Figure 1.1 
 
Figure 1.2 
 
Figure 1.3 
 
 
 
244          M.R. Gorgan et al          Misdiagnosis of cerebral metastases 
 
 
 
 
Figure 1.4 
Figure 1 (1.1, 1.2, 1.3, 1.4) Contrast MRI axial and 
sagital ,T1-left parietal lesion, well delineated, 
attached of dura mater, with moderate surrounding 
edema, suggesting a meningioma. Pathological 
examination after surgery revealed a metastases of a 
papillary adenocarcinoma. 
Discussion 
Treacherous image on a contrast CT 
scan or MRI, with a confusing appearance 
of a single cerebral lesion, is, undoubtedly, 
one of the major source of diagnosis errors. 
This is the reason for which we will take in 
review the most important radiologic data 
related on the degree of confidence of every 
investigation.  
 
CT scan. On noncontrast CT, the density 
of metastatic lesions may be less than, equal to, 
or greater than that of adjacent brain 
parenchyma. Most of the patterns are variable 
and are nondiagnostic. Noncontrast CT is 
performed to detect hemorrhage into 
metastases. Hyperdensity in a metastasis is more 
likely to be hemorrhage than calcification (see 
the image below). 
IV administration of contrast material (30-40 
g iodine) increases the diagnostic accuracy of 
CT. 
 
 
Figure 2.1 
 
Figure 2.2 
Figure 2 (2.1, 2.2) Contrast CT scan revealing a 
right parieto-occipital cystic lesion, with a contrast 
enhancing nodule inside attached from the falx and 
cerebral mantle, with severe mass effect on the 
posterior right ventricular horn, and midline shift, 
suggesting a cystic glioma. Pathological evaluation 
after surgery revealed an undifferentiated carcinoma 
of pulmonary origin (chest x-ray was inconsistent for 
tumor). 
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Figure 3.1 
 
Figure 3.2 
 
Figure 3.3 
 
Figure 3.4 
Figure 3 (3.1, 3.2, 3.3, 3.4) Contrast MRI axial and 
sagital T1, T2- right cystic near-round lesion with a 
fluid content, enhancing contrast peripherally, with 
mass effect and moderate edema, suggesting a 
cerebral abscess. Pathological examination revealed a 
metastasis of a breast carcinoma. Finally a right breast 
small nodule was discovered and treated. 
 
 
Figure 4.1 
 
 
 
246          M.R. Gorgan et al          Misdiagnosis of cerebral metastases 
 
 
 
 
Figure 4.2 
 
Figure 4.3 
 
Figure 4.4 
Figure 4 (4.1, 4.2, 4.3, 4.4) Contrast MRI, axial and 
sagital T1,T2-left temporo-occipital mass lesion 
enhancing contrast marginally, with necrotic content, 
with mass effect on the ventricular horn and midline 
shift, with serious peritumoral edema, suggesting a 
glioblastoma. Postoperative pathological evaluation 
revealed a metastases of colon carcinoma. 
 
 
Figure 5.1 
 
Figure 5.2 
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Figure 5.3 
 
Figure 5.4 
Figure 5 (5.1, 5.2, 5.3, 5.4) Contrast MRI, axial and 
sagital T1,T2-left cerebellar cystic mass lesion, 
enhancing contrast peripherally, with a significant 
contact with the petrous bone in the area of internal 
auditory canal, with mass effect on the brain stem 
and fourth ventricle, suggesting a cerebellar abscess. 
Postoperative pathological examination revealed a 
metastasis of a clear cell carcinoma. 
 
 
 
 
 
 
Figure 6.1 
 
Figure 6.2 
 
Figure 6.3 
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Figure 6.4 
Figure 6 (6.1, 6.2, 6.3, 6.4) Contrast MRI, axial and 
sagital T1,T2- left solid parietal lesion highly contrast 
enhancing, attached on the falx in the posterior third, 
with a severe peritumoral edema, and mass effect 
with midline shift. Content of the lesion in un-
homogenous with necrosis and intratumoral vessels. 
The aspect suggest a atypical falx meningioma. 
Postoperative pathological examination revealed a 
metastasis of a lung epidermoid carcinoma. 
 
 
Figure 7.1 
 
Figure 7.2 
 
Figure 7.3 
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Figure 7.3 
 
Figure 7.4 
Figure 7 (7.1, 7.2, 7.3, 7.4, 7.5) Contrast CT scan 
and contrast MRI, T1, T2- left solid temporo-
occipital lesion attached to the dura, enhancing 
homogenously contrast on the CT and trabecular on 
the MRI, with regional mass effect, invading the 
brain surface, suggesting a superficial glioma. 
Postoperative pathological examination revealed a 
metastasis of highly differentiated adenocarcinoma 
 
Most metastases enhance after a standard 
dose of IV contrast. Use of a higher dose of 
contrast (80-85 g of iodine) and delaying 
scanning by 1-3 hours after injection of the 
contrast agent lead to a further increase in the 
detection of multiple metastases; such an 
approach is appropriate if MRI is not available. 
The detection of additional metastases has 
important diagnostic and therapeutic 
implications. In cases in which there is no 
known primary cancer, if a solitary lesion is 
found on routine enhanced CT, the presence of 
an additional lesion may suggest a metastatic 
process, provided the solitary lesion is believed 
to be a primary lesion. In cases involving a 
solitary metastatic lesion of the brain, detection 
of an additional lesion may have a bearing on 
treatment; with multiple lesions, surgical 
treatment may be forgone in favor of 
chemotherapy, radiation therapy, or both. 
Contrast-enhanced CT is effective in detecting 
major leptomeningeal spread. Contrast-
enhancing subdural or epidural metastases may 
be seen, usually secondary to calvarial lesions. 
Of breast, lung, prostate, and renal-cell 
neoplasms, 5% metastasize to the calvarium; of 
these, 15% extend into the subdural space. 
Degree of confidence. On findings of 
multiple, enhancing solid lesions at the gray 
matter–white matter junction and prominent 
surrounding edema in a patient with known 
primary cancer, a diagnosis of metastases may 
be confidently made. Approximately 90% of 
patients with a history of cancer who present 
with a single supratentorial lesion have brain 
metastases. Patients with multiple lesions are 
even more likely to have metastatic disease. 
Before undergoing definitive therapy, patients 
who are found to have a single metastasis on 
contrast-enhanced CT should undergo a 
contrast-enhanced MRI examination, if facilities 
for such an examination are available. Routine 
cranial CT is useful in the staging of cancer in 
the patient with non–small-cell lung cancer; 
cranial CT has a sensitivity of 92%, a specificity 
of 99%, and an accuracy of 98% in detecting 
brain metastases. Contrast-enhanced CT is 
perhaps the best method to identify calvarial 
metastases. In studies comparing contrast-
enhanced CT with contrast-enhanced MRI, 
approximately 20% of patients who 
demonstrated a single lesion on CT 
demonstrated multiple lesions on MRI. Mostly, 
the lesions missed on contrast-enhanced CT 
were smaller (< 2 cm in diameter) and were 
located next to the bone in a frontotemporal 
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location. Dural-based metastases may mimic 
meningioma. (1, 3, 7, 11, 16) 
Magnetic Resonance Imaging. Multiple 
lesions with marked vasogenic edema and mass 
effect are typically seen in patients with brain 
metastases, as shown in the images below. 
Lesions are isointense to mildly hypointense on 
T1-weighted images; they are hyperintense on 
T2-weighted images or with fluid attenuation 
inversion recovery. Surrounding edema is 
relatively hypointense on fluid attenuation 
inversion recovery and on T1-weighted images; 
they are hyperintense on T2-weighted images. 
Hemorrhagic metastases or melanoma lesions 
are hyperintense on T1-weighted images.On 
T2-weighted images, mucinous 
adenocarcinoma may be hypointense, owing to 
calcification; hemorrhagic metastases may be 
hypointense, owing to the chronic breakdown 
of blood products. Following administration of 
a contrast agent, solid, nodular (see first image 
below), or irregular ring patterns of 
enhancement are seen. Nonenhancing lesions 
(see second image below) are less likely to be 
metastases. Contrast-enhanced MRI is the best 
method for detection of meningeal tumor 
seeding, which appears as abnormal dural 
enhancement. This is a nonspecific finding; 
however, in the correct clinical setting, it 
correlates with the presence of sheets of tumor 
cells affecting the meninges. The usefulness of 
diffusion-weighted and perfusion-weighted 
imaging and proton-MR spectroscopy in the 
initial diagnosis of brain metastases has not been 
established. Gadolinium-based contrast agents 
have been linked to the development of 
nephrogenic systemic fibrosis (NSF) or 
nephrogenic fibrosing dermopathy (NFD). 
NSF/NFD has occurred in patients with 
moderate to end-stage renal disease after being 
given a gadolinium-based contrast agent to 
enhance MRI or MRA scans. NSF/NFD is a 
debilitating and sometimes fatal disease. 
Characteristics include red or dark patches on 
the skin; burning, itching, swelling, hardening, 
and tightening of the skin; yellow spots on the 
whites of the eyes; joint stiffness with trouble 
moving or straightening the arms, hands, legs, 
or feet; pain deep in the hip bones or ribs; and 
muscle weakness. Degree of confidence. 
Gadolinium-enhanced MRI is superior to 
contrast-enhanced CT in the diagnosis of brain 
metastases. Gadolinium-enhanced MRI has the 
following advantages: useful for detecting 
smaller lesions, provides better soft tissue 
contrast, provides relatively stronger 
enhancement with paramagnetic contrast 
agents, no bone artifacts in the images, provides 
less partial-volume effects, particularly for 
lesions adjacent to bones, provides direct 
multiplanar imaging. Use of magnetization 
transfer with single-dose gadolinium 
administration is roughly equivalent to triple-
dose, postcontrast, spin-echo imaging in 
detecting lesions and lesion conspicuity. It has 
been shown that treatment with dexamethasone 
leads to a reduction in evidence on MRI of 
peritumoral edema and, occasionally, a 
lessening in the extent of contrast enhancement. 
If a lesion is found and a definitive diagnosis 
cannot be established, biopsy should be 
performed. Detection of additional lesions is 
important when considering surgical treatment 
of a solitary lesion. Magnetization transfer used 
with routine-dose gadolinium contrast is closely 
comparable to the high-dose technique. False 
positives/negatives.On imaging, dural-based 
metastases may resemble meningioma. 
Leptomeningeal carcinomatosis may resemble 
chronic meningitis; however, an appropriate 
history or detection of primary cancer may be 
sufficient for establishing the diagnosis. 
Leptomeningeal enhancement may occur after 
the administration of radiation or following 
extra-axial hemorrhage; it may also occur below 
a craniotomy site. Single or multiple ring-
enhancing lesions with edema may resemble 
infectious processes. Solitary lesions resemble 
primary brain tumors (5,8,16). 
Nuclear Imaging. Currently, nuclear 
medicine studies are not employed routinely as 
primary imaging techniques for detecting 
intracranial metastatic disease. Typical findings 
are multiple intracerebral areas of increased 
activity. The standard isotope used is 
technetium-99m (99m Tc). On isotope whole-
body bone scans, calvarial metastases may 
appear as multiple focal areas of increased 
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activity. With whole-body 18-
fluorodeoxyglucose (FDG) positron emission 
tomography (PET) used in cancer staging, 
intracerebral metastases may appear as areas of 
increased metabolism. Degree of confidence. 
Radionuclide studies are sensitive but are highly 
nonspecific. In studies involving a small 
number of patients, FDG-PET demonstrated 
low sensitivity and low specificity. Currently, 
FDG-PET is not considered superior to CT or 
MRI in the initial evaluation of suspected brain 
metastases. False positives/negatives. In older 
reports, radionuclide imaging was reported to 
detect intracerebral metastases in approximately 
90% of patients, but the findings were 
nonspecific. Neoplasm, inflammation, 
vascularity, or trauma may cause the abnormal 
uptake. FDG-PET has been reported to detect 
approximately two thirds of brain metastases 
resulting from systemic cancer. (6, 10, 14)  
 
Age is an important factor in judging a 
cerebral metastasis case, mainly because in 
the last 10 years, due to the increased 
accessibility for investigations, an higher 
number of patients are diagnosed with mass 
cerebral lesions, and are routinely having a 
CT or MRI. Another reason is that we 
statistically assist to a decrease of age in 
cancer patients, and to an increase of 
survival of this patients due to specific 
treatment improvements.  
History and symptoms plays an 
important role: most of our cases with so-
called misdiagnosis of cerebral metastases 
had few neurological signs, had a good 
clinical and biological status, ignoring 
maybe a possible neoplastic disease. Clinical 
picture of the individual patient is a reliable 
factor for the correlation of imaging data, in 
order to precise, preoperatively a correct 
diagnosis. 
Table 1 focuses on some of the tumor 
markers often used today. Tests for many 
other markers are available through 
commercial testing labs, but these are not 
commonly used. The list below is limited 
to those tumor markers that are available to 
most doctors and have reliable scientific 
information showing that they are useful. 
The values listed below are average values, 
and most labs will list their own "reference 
ranges". Most of the tests are not screening 
tests, but they are useful instruments to 
monitor the evolution of a tumor under 
treatment. 
A suite of deontological issues appear to 
act as an infringement situation of the 
normal relation between the patient and the 
doctor, and can generate a series of legal 
consequences: the patient and his family 
considers being lied, the supposed 
prognosis presented before surgery will 
appear wrong, life expectancy changes, the 
costs for completing the diagnosis and 
treatment will increase tremendously, and 
the professional reputation of the doctor 
and his team will suffer. Family may 
request penalties for malpraxis. In order to 
avoid such situations, they are three 
methods to clarify them before surgery: 
when clinical condition of the patient 
permits, one can proceed to obtain more 
data by biological tests (tumor markers), 
whole body MRI or CT, PET scan, etc., or 
to proceed to a tumor biopsy. When 
surgical procedure became urgent, and if 
the lesion is somehow unclear and not 
correlated entirely with clinical status, it is 
recommended to avoid a clear-cut 
information and to maintain a reserve 
related to the future of the patient, because 
in about 9-10% of the cases the supposed 
brain tumor maybe a metastasis, and this is 
a fact who changes dramatically all 
situation.  
If a patient over 50 years old, is admitted 
for a brain tumor, and radiologist’s 
interpretation of the data may be un-
conclusive, we need to clarify first if a 
primary cancer exists.  
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TABLE 1 
Actual used tumor markers and conditions associated with elevated levels (adapted from American 
Cancer Society, revised on 03.24.2011). 
Tumor 
marker 
Normal value Primary 
tumor(s) 
Additional associated 
malignancies 
Benign conditions Level above 
which 
benign 
disease is 
unlikely 
Sensitivity 
CA 
27.291,2 
< 38 units per mL Breast cancer Colon, gastric, 
hepatic, lung, 
pancreatic, ovarian, 
and prostate cancers 
Breast, liver, and 
kidney disorders, 
ovarian cysts 
> 100 units 
per mL 
Elevated in about 
33% of early-stage 
breast cancers and 
about 67% of late-
stage breast cancers 
CEA < 2.5 ng per mL 
in nonsmokers < 
5 ng per mL in 
smokers 
Colorectal 
cancer 
Breast, lung, gastric, 
pancreatic, bladder, 
medullary thyroid, 
head and neck, 
cervical, and hepatic 
cancers, lymphoma, 
melanoma 
Cigarette smoking, 
peptic ulcer disease, 
inflammatory bowel 
disease, pancreatitis, 
hypothyroidism, 
cirrhosis, biliary 
obstruction 
>10 ng per 
mL 
Elevated in less than 
25% of early-stage 
colon cancers and 
75% of late-stage 
colon cancers 
  
CA 19-9 < 37 units per mL Pancreatic 
cancer, biliary 
tract cancers 
Colon, esophageal, 
and hepatic cancers 
Pancreatitis, biliary 
disease, cirrhosis 
> 1,000 
units per 
mL 
Elevated in 80% to 
90% of pancreatic 
cancers and 60% to 
70% of biliary tract 
cancers* 
AFP < 5.4 ng per mL Hepatocellular 
carcinoma, 
nonseminomat
ous germ cell 
tumors 
Gastric, biliary, and 
pancreatic cancers 
Cirrhosis, viral 
hepatitis, pregnancy 
> 500 ng 
per mL 
Elevated in 80% of 
hepatocellular 
carcinomas 
 Nonseminomatous 
germ cell tumors: see 
β-hCG below 
β-hCG < 5 mIU per mL Nonseminomat
ous germ cell 
tumors, 
gestational 
trophoblastic 
disease 
Rarely, 
gastrointestinal 
cancers 
Hypogonadal states, 
marijuana use 
> 30 mIU 
per mL 
AFP or β-hCG 
elevated in 85% of 
nonseminomatous 
germ cell tumors; 
elevated in only 20% 
of early-stage 
nonseminomatous 
germ cell tumors 
CA 125 < 35 units per mL Ovarian cancer Endometrial, fallopian 
tube, breast, lung, 
esophageal, gastric, 
hepatic, and 
pancreatic cancers 
Menstruation, 
pregnancy, fibroids, 
ovarian cysts, pelvic 
inflammation, 
cirrhosis, ascites, 
pleural and 
pericardial effusions, 
endometriosis 
> 200 units 
per mL 
Elevated in about 
85% of ovarian 
cancers; elevated in 
only 50% of early-
stage ovarian cancers 
PSA < 4 ng per mL for 
screening 
Undetectable 
level after radical 
prostatectomy 
Prostate cancer None Prostatitis, benign 
prostatic 
hypertrophy, 
prostatic trauma, 
after ejaculation 
> 10 ng per 
mL 
Elevated in more than 
75 percent of organ-
confined prostate 
cancers 
  
Legend: CA = cancer antigen; CEA = carcinoembryonic antigen; AFP = alpha-fetoprotein; β-hCG = beta subunit of 
human chorionic gonadotropin; PSA = prostate-specific antigen.*— The greatest possible sensitivity is 95 percent, 
given that 5% of the population have Lewis-null blood type and are unable to produce the antigen. 
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Thereafter we need to evaluate the case 
and all radiological and medical information 
by ourselves, and to avoid the traps 
resulting from an incorrect correlation of 
data. If radiologist advocates for a malignant 
primary brain tumor (high-grade glioma, 
glioblastoma, etc), we need to inform the 
patient’s family that the prognosis is poor, 
but if a metastasis is confirmed after 
pathological evaluation of the specimen, the 
future of the patient might be the worst. 
Any time when a systemic cancer is 
revealed by a brain metastasis, statistically, 
the total surviving time with or without the 
treatment attain about 6 to 8 months. When 
radiologic data suspects a brain abscess, and 
the patient status does not match with an 
infectious condition, we need to maintain a 
serious doubt about patient’s prognosis, 
until pathologic examination reveals the 
final result. A number of tumors, mainly in 
immune suppressed patients (cirrhosis, 
diabetes mellitus, renal failure, etc ), may 
exhibit a false pus aspect, as a component of 
intratumoral necrosis or subacute 
hemorrhage in different stages of 
resolution. The neurosurgeon is the most 
important decision factor and is the one 
who bears the final responsibility towards 
neurosurgical indication, neurosurgical 
procedure and documented information 
provided to patients and family. 
Conclusions 
Any patient over 50 years old with a 
unique brain lesion must be suspected for a 
cerebral metastases. When doubt exists, 
cerebral biopsy and additional investigations 
should be done. According to the recent 
frequency criteria of cerebral metastases 
versus the total number of cerebral tumors 
in adult, between 30 and 40 % of cases may 
have a cerebral metastases. The patient 
must be evaluated correctly and the 
diagnosis must be affirmed with caution. In 
6 -8% of the patients with cerebral 
metastases, the primary neoplasm remain 
unidentified until the decease. 
Neurosurgical operation is certainly the 
most important step to establish a 
precocious and clear diagnosis. 
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